Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease. 

ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer  

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.

JAB-8263 Monotherapy Demonstrates Early Promise in Myelofibrosis

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

®'s Pipeline Report is a collection of news articles and video interviews on emerging agents that are moving through the oncology pipeline. Much of the news comes from biotech companies with novel cancer drugs in their earliest stages, as well as business acquisitions and mergers. The Pipeline Report features innovative therapies being explored across all malignancies.

Pipeline Report

Pipeline Report Archive

Pipeline Report: November 2020

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

Oncolytics Biotech Launches Trial of Pelareorep/Atezolizumab Combo in Difficult-to-Treat GI Cancers

December 17, 2020 - Merck is set to build a new manufacturing facility to increase its production of TICE Bacillus Calmette–Guérin, tripling its current manufacturing capacity.

Merck to Build New Facility to Meet BCG Demand

Pipeline Report: November 2020

Pipeline Report: November 2020

Latest Conference Coverage